Last reviewed · How we verify
Fenoximone (ENOXIMONE)
Fenoximone works by inhibiting the enzyme Phosphodiesterase 4, which breaks down cyclic adenosine monophosphate (cAMP), a molecule that helps regulate various cellular processes.
Fenoximone, also known as Enoximone, is a small molecule drug that targets Phosphodiesterase 4. It belongs to the enoximone drug class and is used to treat certain conditions. However, its commercial status and approved indications are unknown. As a result, its availability and safety considerations cannot be confirmed. Further research is needed to determine its efficacy and potential side effects.
At a glance
| Generic name | ENOXIMONE |
|---|---|
| Drug class | enoximone |
| Target | cGMP-inhibited 3',5'-cyclic phosphodiesterase A, Phosphodiesterase 4 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Mechanism of action
Think of cAMP as a messenger that helps cells respond to signals. When Phosphodiesterase 4 breaks it down, the signal is lost. By blocking this enzyme, fenoximone allows cAMP to stay active longer, helping cells to respond more effectively to signals.
Approved indications
Common side effects
Key clinical trials
- The International PERForator ANeurysm Registry (PERFAN)
- Unloading in Heart Failure Cardiogenic Shock (NA)
- The Effects of Enoximone in Acute Exacerbation COPD (PHASE4)
- Perioperative Measurements of Diastolic Function in Cardiac Surgery
- Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure (PHASE3)
- ESSENTIAL-"The Studies of Oral Enoximone Therapy in Advanced Heart Failure" (PHASE3)
- Microcirculation Guided Therapy Versus "Standard Treatment" of Severe Sepsis (PHASE4)
- Effects of Beta-Blocker Therapy and Phosphodiesterase Inhibition on Cardiac Neurohormonal Activation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fenoximone CI brief — competitive landscape report
- Fenoximone updates RSS · CI watch RSS